Home/Pipeline/Prognostic Test for Prostate Cancer

Prognostic Test for Prostate Cancer

Prostate Cancer Prognosis

ApprovedCommercial

Key Facts

Indication
Prostate Cancer Prognosis
Phase
Approved
Status
Commercial
Company

About Myriad Genetics

Myriad Genetics is a pioneer in genetic testing, having discovered the BRCA1/2 genes and launched the first commercial hereditary cancer risk test. With over 30 years of experience, the company now performs over 1 million genetic tests annually and serves more than 51,000 active ordering physicians. Myriad's mission is to advance health and well-being for all by providing clear, actionable genetic insights that empower personalized healthcare decisions.

View full company profile